Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study

The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

(2013) Kathleen N. Ly et al.   ANNALS OF INTERNAL MEDICINE

Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission

(2013) M. T. Catanese et al.   JOURNAL OF VIROLOGY

HCV’s days are numbered: next-generation direct-acting antivirals and host-targeting agents

(2012) Beatriz Calle Serrano et al.   ANTIVIRAL THERAPY

ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection

(2012) Jill Hochreiter et al.   ANTIVIRAL THERAPY

Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals

(2012) Haihong Zhu et al.   JOURNAL OF INFECTIOUS DISEASES

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

A genetically humanized mouse model for hepatitis C virus infection

(2011) Marcus Dorner et al.   NATURE

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Claudin Association with CD81 Defines Hepatitis C Virus Entry

(2010) Helen J. Harris et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors

(2010) Andrew J. Syder et al.   JOURNAL OF HEPATOLOGY

Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies

(2010) Mirjam B. Zeisel et al.   JOURNAL OF HEPATOLOGY

Mutations within a Conserved Region of the Hepatitis C Virus E2 Glycoprotein That Influence Virus-Receptor Interactions and Sensitivity to Neutralizing Antibodies

(2010) S. Dhillon et al.   JOURNAL OF VIROLOGY

Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI Inhibitor

(2009) David Masson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

(2009) Alexander Ploss et al.   NATURE

Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies

(2008) J. Grove et al.   JOURNAL OF VIROLOGY